PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
8935.00 - 9125.00
6347.00 - 10045.00
380.0K / 335.9K (Avg.)
23.15 | 391.09
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
4.25%
Revenue growth exceeding 1.5x Medical - Pharmaceuticals median of 0.56%. Joel Greenblatt would investigate if growth quality matches quantity.
3.67%
Cost growth of 3.67% versus flat Medical - Pharmaceuticals costs. Walter Schloss would verify cost control.
6.66%
Gross profit growth exceeding 1.5x Medical - Pharmaceuticals median of 1.24%. Joel Greenblatt would investigate competitive advantages.
2.31%
Margin expansion exceeding 1.5x Medical - Pharmaceuticals median of 0.01%. Joel Greenblatt would investigate competitive advantages.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-2.04%
Other expenses reduction while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate advantages.
-1.60%
Operating expenses reduction while Medical - Pharmaceuticals median is -0.44%. Seth Klarman would investigate advantages.
2.77%
Total costs growth exceeding 1.5x Medical - Pharmaceuticals median of 0.13%. Jim Chanos would check for waste.
No Data
No Data available this quarter, please select a different quarter.
-1.86%
D&A reduction while Medical - Pharmaceuticals median is 1.02%. Seth Klarman would investigate efficiency.
29.91%
EBITDA growth exceeding 1.5x Medical - Pharmaceuticals median of 1.39%. Joel Greenblatt would investigate advantages.
24.61%
EBITDA margin growth exceeding 1.5x Medical - Pharmaceuticals median of 0.21%. Joel Greenblatt would investigate advantages.
51.13%
Operating income growth exceeding 1.5x Medical - Pharmaceuticals median of 3.65%. Joel Greenblatt would investigate advantages.
44.97%
Margin change of 44.97% versus flat Medical - Pharmaceuticals. Walter Schloss would verify quality.
1.22%
Other expenses growth while Medical - Pharmaceuticals reduces costs. Peter Lynch would examine differences.
45.93%
Income change of 45.93% versus flat Medical - Pharmaceuticals. Walter Schloss would verify quality.
39.98%
Margin change of 39.98% versus flat Medical - Pharmaceuticals. Walter Schloss would verify quality.
43.90%
Tax expense change of 43.90% versus flat Medical - Pharmaceuticals. Walter Schloss would verify strategy.
46.91%
Income change of 46.91% versus flat Medical - Pharmaceuticals. Walter Schloss would verify quality.
40.92%
Margin change of 40.92% versus flat Medical - Pharmaceuticals. Walter Schloss would verify quality.
46.89%
EPS change of 46.89% versus flat Medical - Pharmaceuticals. Walter Schloss would verify quality.
46.89%
Diluted EPS change of 46.89% versus flat Medical - Pharmaceuticals. Walter Schloss would verify quality.
-0.00%
Share count reduction while Medical - Pharmaceuticals median is 0.13%. Seth Klarman would investigate strategy.
No Data
No Data available this quarter, please select a different quarter.